The total capital raised by the company in 2.5 years is nearly $80 million, and ImCheck is using this to fund the initial clinical trial for the monoclonal antibody ICT01, to further expand the pipeline of immunomodulators targeting the butyrophilins super-family, and to bring additional immuno-oncology antibody programs into the clinic.

ImCheck’s translational research platform, where the company conducts its discovery and development research for a new generation therapeutic antibodies, has bee